US regulator investigates tumour risk in children given Novartis gene therapy
Summary
The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including malignancy, associated with Novartis’ gene therapy Zolgensma. The Swiss drug maker earlier in the day disclosed two cases in which tumours in children showed evidence of being linked to its gene therapy drug used to treat patients less than two years old with spinal muscular atrophy. Novartis said that it had received nine reports overall of tumours in patients...
Description from South China Morning Post.
Who is covering this
-
US regulator investigates tumour risk in children given Novartis gene therapy
The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including malignancy, associated with Novartis’ gene therapy Zolgensma. The Swiss drug maker earlier in the day disclosed two cases in which tumours in children...
Related stories
FDA scientists opposed Trump administration’s move to ease peptide access
Trump administration says biggest changes coming to infant formula in nearly 30 years
Actor Ajay Devgn moves High Court against FDA notice over Vimal Elaichi ads
Blood pressure medication recalled nationwide
A new HIV-prevention drug is showing promising signs, but it's difficult to find in Africa and beyond
Comments
Comments need JavaScript.